script.reportAU
Rheumatology

Adalimumab

Brand: Hyrimoz

PBAC's latest decision on Adalimumab: Recommended with restriction (2024). Considered for Severe Crohn disease, moderate to severe ulcerative colitis, severe active juvenile idiopathic arthritis, complex refractory fistulising Crohn disease, severe active rheumatoid arthritis, severe psoriatic arthritis, ankylosing spondylitis, severe chronic plaque psoriasis, moderate to severe hidradenitis suppurativa, and vision-threatening non-infectious uveitis.

PBAC outcome
Recommended with restriction
Authority Required
ICER (AUD/QALY)
Cost-min
cost-minimisation analysis
Submissions
41
first 2006
PBS spend
$246M
355,511 scripts · 2024

Eligible population

Patients with severe Crohn disease, moderate to severe ulcerative colitis, severe active juvenile idiopathic arthritis, complex refractory fistulising Crohn disease, severe active rheumatoid arthritis, severe psoriatic arthritis, ankylosing spondylitis, severe chronic plaque psoriasis, moderate to severe hidradenitis suppurativa, and vision-threatening non-infectious uveitis.

Therapy area
Rheumatology
Line of therapy
Any
Evidence base
RCT
Primary endpoint
Other
Pivotal trial size
465 patients
Key trials
CGPN017B12101, GP17-104, GP17-301
Comparator
Humira (reference brand) and other biosimilar brands of adalimumab
Economic model
Cost-minimisation
ICER note
Cost-minimisation submission. No economic model presented as this is a Category 4 submission (biosimilar listing with same circumstances as reference brand).
ICER (historical)
$45k/QALY–$75k/QALY across 3 submissions (2013–2016) — the latest submission carried no numeric base case. No single PSD states this combined range; see source PSDs.

PBS expenditure

The Australian government paid $246M in PBS benefits for Adalimumab in 2024 across 355,511 scripts, at $693 per script.

Submission history

Similar precedents

Open on full dashboard →